Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Maxinovel Pharmaceuticals Announces the Presentation of Its Orally Active PD-1/PD-L1 Inhibitors in 2018 AACR

Maxinovel Pharmaceuticals,Inc.
Posted on: 26 Feb 18

Maxinovel Pharmaceuticals today announces that it will present preclinical results of its orally active PD-1/PD-L1 inhibitors as a single agent or combination with Epacadostat, Celebrex, Cisplatin and CTLA-4, respectively. The presentation will be held in 2018 AACR in Chicago, USA. The details are as follows:

Title: Novel small molecule inhibitors of PD-1/PD-L1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel and Canonical Targets

Session Date and Time: Tuesday April 17, 2018 8:00am-12:00pm

Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 17

Permanent Abstract Number: 3851

About Maxinovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005313/en/

Business Wire
www.businesswire.com

Last updated on: 26/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.